Atrimustine

CAS : 75219-46-4

Ref. 3D-ADA21946

Informations sur le produit

• Nom: Atrimustine
• Synonymes: (17Beta)-17-({[(4-{4-[Bis(2-Chloroethyl)Amino]Phenyl}Butanoyl)Oxy]Acetyl}Oxy)Estra-1,3,5(10)-Trien-3-Yl Benzoate, 17β-Busramustine, Bestrabucil, Estra-1,3,5(10)-triene-3,17-diol (17β)-, 3-benzoate 17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]acetate], Estra-1,3,5(10)-triene-3,17-diol (17β)-, 3-benzoate 17-[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]acetate], Estra-1,3,5(10)-triene-3,17-diol (17β)-, 3-benzoate 17-[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]acetate], (3β,5β)-, Km 2210

Description

Atrimustine is a molecule that binds to the cb2 receptor and inhibits the growth of cells in autoimmune diseases. It is also an analog of hydroxyl group and can be used as a diagnostic agent for various types of cancer. Atrimustine has been shown to inhibit the activity of receptors such as the growth factor receptor, fatty acid, colony-stimulating factor, or metabolic disorders. The drug has been found to be biocompatible with polymer implants and may have applications in infectious diseases.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 720.7 g/mol
• Formule: C₄₁H₄₇Cl₂NO₆
• Degré de pureté: Min. 95%